Literature DB >> 26958620

Dataset for genotyping validation of cytochrome P450 2A6 whole-gene deletion (CYP2A6*4) by real-time polymerase chain reaction platforms.

Makiko Shimizu1, Tomoki Koyama1, Izumi Kishimoto1, Hiroshi Yamazaki1.   

Abstract

This data article contains a supplementary figure and validation data relating to the research article entitled "Genotyping of wild-type cytochrome P450 2A6 and whole-gene deletion using human blood samples and a multiplex real-time polymerase chain reaction method with dual-labeled probes" (Shimizu et al., Clinica Chimica Acta 441, 71-74, 2015), which presents a multiplex real-time polymerase chain reaction method with dual-labeled probes for human P450 2A6 wild-type and whole-gene deletion. Real-time methods have dramatically improved the speed of complex genetic diagnostics compared to conventional assays based on restriction enzyme digestion. Here, we show the basic assay validation data by single and multiplex determinations in comparison with commercial TaqMan copy number assays for P450 2A6.

Entities:  

Keywords:  CYP2A6*1; CYP2A6*4; Copy number assays; Real-time PCR; TaqMan; Whole-gene deletion

Year:  2015        PMID: 26958620      PMCID: PMC4773388          DOI: 10.1016/j.dib.2015.10.019

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specifications table Value of the data A real-time polymerase chain reaction (PCR) assay for cytochrome P450 2A6 genotyping recently developed [1] was fully validated using a conventional PCR-restriction fragment length polymorphism (RFLP) method (Fig. 1).
Fig. 1

A representative gel image for genotyping of human P450 2A6 (P450 2A6*1A, 2A6*1B, and 2A6*4) by PCR-RFLP [2], [3], [4] separated on 2% agarose gel. The PCR products of P450 2A6*1A (1323 bp) and 2A6*1B (1322 bp) with a forward primer named 2A6 B4 (5′-CACCGAAGTGTWCCCTATGCTG-3′) and a reverse primer named 2A6 UTR AS-1 (5′-TGTAAAATGGGCATGAACGCCC-3′) [2], [3], [4] were digested by FokI into fragments of 573, 513, 148, and 89 bp and fragments of 661, 513, and 148 bp, respectively. The PCR products of P450 2A6*4 (1309 bp) were digested by FokI into fragments of 661, 411, 148, and 89 bp.

Aside from the PCR-based methods outlined in this report, commercially available TaqMan assays for copy number determinations (whole-gene deletion P450 2A6*4 genotyping in regions of limited homology) were almost validated (Table 1).
Table 1

Comparison of genotyping of P450 2A6 of 45 individuals in a Japanese population by conventional PCR (Fig. 1), multiplex real-time PCR [1], and three positions for TaqMan methods (07545274, 04488984, and 07545275).

PCR-RFLP, FokIMultiplex real-time PCRTaqMan
PCR-RFLP, FokIMultiplex real-time PCRTaqMan
075452740448898407545275075452740448898407545275
*1A/*1A*1/*11.81.92.4*1B/*1B*1/*11.81.92.2
*1A/*1A*1/*12.01.92.3*1B/*1B*1/*11.72.12.4
*1A/*1A*1/*11.82.12.4*1B/*1B*1/*11.91.82.4
*1A/*1A*1/*12.02.02.0*1B/*1B*1/*12.22.02.5
*1A/*1A*1/*12.02.12.1*1B/*1B*1/*12.11.72.1
*1A/*1A*1/*12.22.32.3*1B/*1B*1/*12.22.52.1
*1A/*1B*1/*11.81.61.7*1B/*1B*1/*12.52.82.3
*1A/*1B*1/*11.92.02.4*1B/*1B*1/*12.12.12.2
*1A/*1B*1/*12.12.12.2*1B/*1B*1/*11.71.82.2
*1A/*1B*1/*12.21.82.4*1A/*4*1/*41.11.01.2
*1A/*1B*1/*11.91.92.0*1A/*4*1/*41.41.41.2
*1A/*1B*1/*11.92.02.4*1A/*4*1/*41.31.31.5
*1A/*1B*1/*11.81.92.2*1A/*4*1/*41.01.21.0
*1A/*1B*1/*11.92.32.4*1A/*4*1/*41.01.31.2
*1A/*1B*1/*11.51.92.5*1B/*4*1/*41.11.01.3
*1A/*1B*1/*12.12.02.5*1B/*4*1/*41.20.91.4
*1A/*1B*1/*12.12.51.7*1B/*4*1/*41.21.31.2
*1A/*1B*1/*12.02.32.5*1B/*4*1/*41.21.31.3
*1A/*1B*1/*11.92.32.5*1B/*4*1/*41.01.21.1
*1A/*1B*1/*12.02.02.0*1B/*4*1/*41.01.11.2
*1A/*1B*1/*11.72.21.7*4/*4*4/*40.10.10.1
*1B/*1B*1/*10.91.31.1*4/*4*4/*40.20.20.2
*1B/*1B*1/*11.61.92.2

Bold and italic copy numbers obtained by the TaqMan system were not consistent with the genotyping by conventional PCR and multiplex real-time PCR [1]. A representative PCR-RFLP gel after FokI digestion for P450 2A6*1A, *1B and *4 are shown in Fig. 1.

Genotyping strategies for P450 2A6 wild-type (P450 2A6*1) and whole-gene deletion (P450 2A6*4) alleles defined here could be combined with highly automated genome-wide association studies, which have limited utility for identifying whole-gene deletions. The dataset that supports the genotyping validations of human P450 2A6 wild-type and whole gene deletion are provided by single and multiplex determinations in comparison with commercial TaqMan copy number assays.

1. Data

Validation of genotyping of human wild-type P450 2A6*1 and whole-gene deletion P450 2A6*4 by both PCR-RFLP and real-time platforms was carried out. One of the 45 subjects (genotyped as P450 2A6*1B/*1B, Table 1) was not matched in term of P450 2A6 copy numbers (around 1) in the current TaqMan analysis.

2. Experimental design, materials and methods

The ethics committee of Showa Pharmaceutical University approved this analysis in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki). Informed consent was obtained for experimentation from all subjects. Genotyping of P450 2A6 (P450 2A6*1A, 2A6*1B, and 2A6*4) was carried out by conventional PCR amplification (Fig. 1) as described previously [2], [3], [4]. Blood samples were obtained with puncture needles, lysed, and stabilized [5]. Blood samples from healthy non-smoking Japanese volunteers or DNA fractions extracted separately by the standard protocol from the volunteers׳ buccal cells were used for real-time detection of P450 2A6 wild-type and whole-gene deletion [1]. The samples also underwent TaqMan Copy Number Assays (Hs07545274, Hs04488984, and Hs07545275; ThermoFisher Scientific, Waltham, MA, USA). The P450 2A6 copy numbers in the human genomes were calculated using CopyCaller software according to the manufacturer׳s instructions with designed human RNase P TaqMan Copy Number Reference Assays (4403326; ThermoFisher Scientific) after duplex real-time PCR reactions.

Conflicts of interest

None.
Subject areaBiology

More specific subject areaHuman molecular genetics
Type of dataTable, gel image, text file
How data was acquiredApplied Biosystems 7300 Real-Time PCR System
Data formatAnalyzed data, validated with three independent methods.
Experimental factorsHuman blood drop samples and DNA fractions obtained from 45 Japanese individual subjects.
Experimental featuresA rapid detection assay of wild-type and whole-gene deletion-type of human P450 2A6 by multiplex real-time polymerase chain reaction and commercially available TaqMan assays for P450 2A6 copy number determinations were validated.
Data source locationShowa Pharmaceutical University, Machida, Tokyo, Jc,apan
Data accessibilityThe data are supplied with this article.
  3 in total

1.  Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers.

Authors:  Masaki Fujieda; Hiroshi Yamazaki; Tetsuya Saito; Kazuma Kiyotani; Maxwell Afari Gyamfi; Masaharu Sakurai; Hirotoshi Dosaka-Akita; Yuichi Sawamura; Jun Yokota; Hideo Kunitoh; Tetsuya Kamataki
Journal:  Carcinogenesis       Date:  2004-08-12       Impact factor: 4.944

2.  Sample-to-SNP kit: a reliable, easy and fast tool for the detection of HFE p.H63D and p.C282Y variations associated to hereditary hemochromatosis.

Authors:  Peter B Nielsen; Maja S Petersen; Viviana Ystaas; Rolf V Andersen; Karin M Hansen; Vibeke Blaabjerg; Mette Refstrup
Journal:  Gene       Date:  2012-06-23       Impact factor: 3.688

3.  Genotyping of wild-type cytochrome P450 2A6 and whole-gene deletion using human blood samples and a multiplex real-time polymerase chain reaction method with dual-labeled probes.

Authors:  Makiko Shimizu; Ren Sawaya; Izumi Kishimoto; Hiroshi Yamazaki
Journal:  Clin Chim Acta       Date:  2014-12-19       Impact factor: 3.786

  3 in total
  4 in total

1.  Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity.

Authors:  Ahmed El-Boraie; Taraneh Taghavi; Meghan J Chenoweth; Koya Fukunaga; Taisei Mushiroda; Michiaki Kubo; Caryn Lerman; Nicole L Nollen; Neal L Benowitz; Rachel F Tyndale
Journal:  Addict Biol       Date:  2019-02-27       Impact factor: 4.280

2.  Pharmacogenomics of Nicotine Metabolism: Novel CYP2A6 and CYP2B6 Genetic Variation Patterns in Alaska Native and American Indian Populations.

Authors:  Katrina G Claw; Julie A Beans; Seung-Been Lee; Jaedon P Avey; Patricia A Stapleton; Steven E Scherer; Ahmed El-Boraie; Rachel F Tyndale; Deborah A Nickerson; Denise A Dillard; Kenneth E Thummel; Renee F Robinson
Journal:  Nicotine Tob Res       Date:  2020-05-26       Impact factor: 4.244

3.  Accuracy and applications of sequencing and genotyping approaches for CYP2A6 and homologous genes.

Authors:  Alec W R Langlois; Ahmed El-Boraie; Koya Fukunaga; Taisei Mushiroda; Michiaki Kubo; Caryn Lerman; Jo Knight; Steven E Scherer; Meghan J Chenoweth; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2022-02-21       Impact factor: 2.000

4.  Candidate SNP markers of reproductive potential are predicted by a significant change in the affinity of TATA-binding protein for human gene promoters.

Authors:  Irina V Chadaeva; Petr M Ponomarenko; Dmitry A Rasskazov; Ekaterina B Sharypova; Elena V Kashina; Dmitry A Zhechev; Irina A Drachkova; Olga V Arkova; Ludmila K Savinkova; Mikhail P Ponomarenko; Nikolay A Kolchanov; Ludmila V Osadchuk; Alexandr V Osadchuk
Journal:  BMC Genomics       Date:  2018-02-09       Impact factor: 3.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.